Merkel cell carcinoma in Turkey: A multicentric study

Basit Öğe Kaydı
dc.authoridBilici, Ahmet/0000-0002-3192-456X
dc.authoridPaydas, Semra/0000-0003-4642-3693
dc.authoridUysal, Mukremin/0000-0002-8524-0665
dc.authoridDemiray, Aydın/0000-0002-3343-0184
dc.authoridAksoy, Sercan/0000-0003-4984-1049
dc.authoridDEMİRAY, ATİKE GÖKÇEN/0000-0003-4397-5468;
dc.authorwosidBilici, Ahmet/E-2062-2018
dc.authorwosidArslan, Cagatay/I-1932-2016
dc.authorwosidPaydas, Semra/F-3132-2018
dc.authorwosidUysal, Mukremin/B-8956-2014
dc.authorwosidDemiray, Aydın/AEN-1780-2022
dc.authorwosidAksoy, Sercan/S-2480-2019
dc.authorwosidTufan, Gulnihal/HIZ-9729-2022
dc.contributor.authorYildiz, Fatih
dc.contributor.authorDemirci, Umut
dc.contributor.authorKucukarda, Ahmet
dc.contributor.authorBuyuksimsek, Mahmut
dc.contributor.authorSakalar, Teoman
dc.contributor.authorTopcu, Turkan Ozturk
dc.contributor.authorAslan, Ferit
dc.date.accessioned2024-06-12T10:56:36Z
dc.date.available2024-06-12T10:56:36Z
dc.date.issued2021
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground: Merkel cell carcinoma (MCC) is a rare but highly aggressive neuroendocrine carcinoma of the skin. In this study, we aimed to evaluate the clinicopathologic characteristics, treatment outcomes, and survival of MCC cases in Turkey. Materials and Methods: The patients diagnosed with MCC between 1999 and 2018 at twenty different centers in Turkey were included in the study. Patient and tumor characteristics and adjuvant and metastatis treatment outcomes were analyzed retrospectively. Results: The median age of totally 89 patients was 70 (26-93). The most common primary location was lower limbs (n = 29, 32.5%). Immunohistochemically, CK20 positivity was present in 59 patients (66.3%). Only two patients had secondary malignancy. The majority of the patients (n = 76, 85.4%) were diagnosed at the localized stage. Surgery was performed for all patients in the early stage, and adjuvant radiotherapy or/and chemotherapy was applied to 52.6% (n = 40) of nonmetastatic patients. The median follow-up was 29 months. Recurrence developed in 21 (27.6%) of the 76 patients who presented with local or regional disease. Two-year disease-free survival (DFS) was 68.1% and 5-year DFS was 62.0% for localized stage. The 5-year DFS was similar for patients receiving adjuvant treatment (chemotherapy, radiotherapy, or sequential chemoradiotherapy) and without adjuvant therapy (P > 0.05). Two-year overall survival in patients who presented with localized disease was 71.3% and 18.5% in metastatic patients (P < 0.001). In the metastatic stage, platinum/etoposide combination was the most preferred combination regimen. Median progression-free survival (PFS) in first-line chemotherapy was 7 months (95% confidence interval: 3.5-10.5 months; standart error: 1.78). Conclusions: Although MCC is rare in Turkey, the incidence is increasing. Gender, CK20 status, tumor size, lymph node involvement, and adjuvant treatment were not associated with recurrence.en_US
dc.identifier.doi10.4103/jcrt.JCRT_950_19
dc.identifier.endpage1529en_US
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.issue6en_US
dc.identifier.pmid34916389en_US
dc.identifier.scopus2-s2.0-85121898572en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1525en_US
dc.identifier.urihttps://doi.org/10.4103/jcrt.JCRT_950_19
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19853
dc.identifier.volume17en_US
dc.identifier.wosWOS:000754558000034en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofJournal Of Cancer Research And Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCK20en_US
dc.subjectMerkel Cell Carcinomaen_US
dc.subjectNeuroendocrin Carcinomaen_US
dc.subjectSkin Carcinomaen_US
dc.subjectStage-Ien_US
dc.subjectSurvivalen_US
dc.subjectChemotherapyen_US
dc.subjectSeriesen_US
dc.subjectRisken_US
dc.titleMerkel cell carcinoma in Turkey: A multicentric studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu